Nuvilex (NVLX) Creating a Type of “Artificial Pancreas” to Cut Into $245 Billion Cost of Diabetes
The American Diabetes Association said this month that diabetes cost the United States an estimated $245 BILLION in 2012. That’s a 40 percent increase from six years ago, simply due to more and more people are being diagnosed at a distressing rate. At the end of last year, 22.3 million people, or 7% of the United States population, will have diabetes. The International Diabetes Federation estimated that 366 MILLION individuals were diagnosed with diabetes in 2011 (about 180 million more were approximated to be undiagnosed) and that amount is expected to grow to 552 MILLION by 2030, if “urgent action” is not taken straightaway. That’s 1 in every 10 people on the planet! Unbelievably, the number is estimated to increase to 1 in every 3 people on the planet by 2050 at its current rate of growth. Is there any surprise why the government, who foots the check for about 62% of the costs, met on Capitol Hill to determine how to curtail the mounting costs?
“We have an incredible epidemic of diabetes that is driving health care expenses excessively. ... Unless we do something to stop diabetes, the economic toll will continue to grow,” said the American Diabetes Association’s Chief Scientific and Medical Officer, Robert E. Ratner, MD, at a recent meeting on Capitol Hill.
Now, you don’t have to be a mathematician, economist, politician, or be someone who has received a higher learning of any type to conclude what a drain diabetes is on the country and that an answer MUST be discovered, especially with all of the budget bickering going on in DC at this moment. Remember those cost numbers are just for the U.S. Can you fathom the true cost world-wide? There’s a good reason that Congress has tasked the FDA to expedite new medications to the market that meet areas of great unmet medical need, like diabetes, the single most expensive long-term disease known to man. Investors take notice; find a company that has a promising solution NOW!
The cost of diabetes in the U.S. has increased 40% in 5 years to a mammoth $245 BILLION in 2012! 7% of the U.S. population has diabetes now. At the current rate, 33% of the world’s population will have diabetes in 2050!
There are $80 per share companies like Johnson & Johnson (NYSE: JNJ) that have a promising diabetes medicine that is expected to garner FDA approval in March, but the approval is already baked-into the price per share and at $80, the potential is definitely limited. Undervalued and undiscovered options like Nuvilex, Inc. (OTCBB: NVLX) are the companies that have unparalleled potential. At 4.3 cents, the biotech – who is preparing for late-stage clinical trials with their pancreatic cancer treatment – commands an extremely low market capitalization and an equally attractive price point for the seasoned investor.
Nuvilex’s cell encapsulation technology is the type of acute need technology that could have a significant effect on the diabetes industry. Groundbreaking work in a well documented study called the “Edmonton Protocol” showed that pancreatic islet cell (insulin-producing cells) transplantations could hold the solution to a life-changing diabetes therapy by eliminating the need for daily administration of insulin either by injection or by using an insulin “pump.” However, the problem was that the cells used were allogeneic (derived from a donor different from the recipient) and powerful immunosuppressive medications were required virtually for the duration of the patients’ lives to hinder the recipient’s immune system from going after and terminating the implanted islet cells. It doesn’t take a specialist to realize that permanently curbing a patient’s immune system is obviously not a good idea. Nuvilex’s cell encapsulation technology possibly has the answer, as reinforced by preclinical research in animals that could potentially bring pancreatic islet cell transplants to the hundreds of millions of people in need.
Nuvilex did what many might think to be impossible. Read closely. They took pancreatic inset cells from pigs and encapsulated them with their unique technology. In other words, they put the cells inside of tiny, cellulose-based, capsules that have pores in them so that nutrients for the cells can go in and waste products from the cells as well as “beneficial” factors from the cells can leave; in this situation, the “beneficial” factor was insulin. They then implanted the encapsulated islet cells into diabetes suffering rats. Within a few days, the sugar level of the rats normalized and stayed that way for the 180 days of the study! When the capsules were removed from the rats, the cells inside were still alive and operative – an amazing finding in its own right.
The company also appears to have bypassed the allogeneic issue! Although islet cells from one species (pigs) were implanted into a totally different species (rats), the islet cells inside the capsules were protected from the recipients’ immune systems due to the pores in the capsules are too miniscule to allow immune system cells to enter the capsules and extinguish the islet cells inside them and too miniscule to permit the encapsulated islet cells to escape and then be demolished.
In essence, Nuvilex has figured out a way to invent a type of “artificial” pancreas to control sugar levels, effectively eliminating the need for daily, or recurrent, insulin administration. Remarkable. The company has plans to repeat animal testing on a larger scale and then, if their preliminary conclusions are duplicated, will pursue conducting clinical trials to see if it will prove out in humans as well.
Preclinical animal studies proved that Nuvilex was able to take insulin-producing cells from one species and implant them into a different animal and essentially create a type of “artificial pancreas” to combat diabetes!
This is literally an “are you kidding me?”-type of a moment that Nuvilex was able to complete this preliminary study with such encouraging results. Many investors love the company because of the compelling Phase 2 clinical research done with its cell encapsulation technology on advanced pancreatic cancer which demonstrated the potential of the technology because the clinical trial results outdid the historic results of the only FDA-approved single medication treatment for advanced, inoperable, pancreatic cancer. Others foresee great worth in the company’s Medical Marijuana Sciences subsidiary that will try to demonstrate the benefits of ingredients of marijuana in the development of treatments for the most devastating strains of cancer. Few have had a grasp on how Nuvilex’s unique cell encapsulation technology can be used in one of the biggest markets in the world, especially diabetes. Now you do.
Unsubscribe | Disclaimer
10200 Forest Green Blvd, Ste 112, Louisville, Kentucky 40223
Nessun commento:
Posta un commento